A dynamic expression of EpCAM was shown in esophageal cancer throughout tumor progression, where EpCAMhigh phenotypes correlated with proliferative stages, whereas EpCAMlow/negative phenotypes were associated with migration, invasion and dissemination, suggesting that differing expression levels of EpCAM occur during cancer progression and must be taken into consideration for therapeutic approaches and during clinical retrieval of disseminated tumor cells [29]. This evidence concerns the gene EPCAM and cancer.